Ceapro Inc. ("Ceapro" or the "Company"), a growth-stage biotechnology company focused on the development and commercialization of active ingredients for healthcare and cosmetic industries, announced today that an abstract on its novel Pressurized Gas eXpanded (PGX) platform processing technology will be presented at the 12th Annual BIO World Congress on Industrial Biotechnology being held July 19-22, 2015, at the Montréal Convention Center, in Montréal, Canada.
Bernhard Seifried, Ph.D., Ceapro's Senior Research Scientist and a co-inventor of PGX, will make a presentation entitled, "PGX Technology: a platform technology for novel biopolymer applications," during a poster session focused on speciality chemicals, food and nutritional ingredients. Dr. Seifried will discuss Ceapro's unique and disruptive PGX enabling technology for drying aqueous solutions or dispersions of high molecular weight biopolymers, such as starch, polysaccharides, gums, pectins or cellulose nanocrystals.
About the BIO World Congress on Industrial Biotechnology
The BIO World Congress on Industrial Biotechnology is the world's largest industrial biotechnology event bringing together 1,300+ leaders, investors, and policy makers in advanced biofuels, biobased products and renewable chemicals. For more information please visit
About Pressurized Gas eXpanded Liquid Technology (PGX)
PGX is a unique and disruptive technology with several key advantages over conventional drying and purification technologies that can be used to process biopolymers into high-value, nano-sized polymer structures and novel bio-nanocomposites. PGX is ideally suited for processing challenging high-molecular-weight, water-soluble biopolymers. It has the ability to make ultra-light, highly porous polymer structures on a continuous basis, which is not possible using today's conventional technologies. PGX was co-invented by Ceapro researcher Dr. Bernhard Seifried and University of Alberta professor, Dr. Feral Temelli.
About Ceapro Inc.
Ceapro Inc. is a Canadian biotechnology company involved in the development of proprietary extraction technology and the application of this technology to the production of extracts and "active ingredients" from oats and other renewable plant resources. Ceapro adds further value to its extracts by supporting their use in cosmeceutical, nutraceutical, and therapeutics products for humans and animals. The Company has a broad range of expertise in natural product chemistry, microbiology, biochemistry, immunology and process engineering. These skills merge in the fields of active ingredients, biopharmaceuticals and drug-delivery solutions. For more information on Ceapro, please visit the Company's website at www.ceapro.com.